PIK3CA and head and neck squamous cell carcinoma: Whether NSAID use protects against the development of HNSCC remains controversial, as results have been mixed or inconclusive.7,8,9,10,11 Recently, however, Hedberg et al found that regular NSAID use at any time improves disease-specific survival (DSS) and overall survival (OS) in patients with PI3K-altered HNSCC.12 Less explored is the association of NSAID use with definitive chemoradiation therapy (CRT).